<DOC>
	<DOCNO>NCT01586364</DOCNO>
	<brief_summary>The objective study ass long-term safety daily dose ospemifene 60 mg treatment vulvar vaginal atrophy ( VVA ) postmenopausal woman without uterus .</brief_summary>
	<brief_title>Long-Term Safety Ospemifene 60 mg Oral Daily Dose Treatment Vulvar Vaginal Atrophy ( VVA ) Postmenopausal Women Without Uterus</brief_title>
	<detailed_description />
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Vaginal Diseases</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>Postmenopausal woman age 40 80 year diagnosis vulvar vaginal atrophy ( VVA ) assess vaginal pH , maturation index vaginal smear , selfreported symptom Baseline Protocol 1550310 Did uterus Met inclusion exclusion criterion Protocol 1550310 Had complete Protocol 1550310 without clinically significant abnormal finding endofstudy visit Protocol 1550310 Provided write informed consent participate study agree follow dosing instruction complete require study visit Had clinically significant abnormal finding Week 12 End Study visit Protocol 1550310 Had physical mental condition , opinion investigator , may interfere subject 's ability comply study procedure</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Menopausal symptom</keyword>
	<keyword>Vulvar vaginal atrophy menopausal woman</keyword>
	<keyword>Vaginal atrophy</keyword>
	<keyword>Urogenital atrophy</keyword>
</DOC>